Overview

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.

Phase:

Phase 2

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel